Source: TH
Subject: Role of Women and Women’s Organization, Population and Associated Issues
Context: Women face growing health and safety risks from rising heat, a new MSSRF study shows. Meanwhile, WHO signals cautious approval for weight-loss drugs, India intensifies action on antibiotic resistance, and South Africa advances with a promising HIV prevention shot.
About Climate Stress on Women and the Evolving Global Health Response:
What is the issue?
- Heat-linked morbidity among women – Rising temperatures are directly correlating with specific reproductive and mental health crises in women, particularly in high-heat districts.
E.g. A 2024 MSSRF study in Beed (Maharashtra) found that female sugarcane workers in high-heat zones reported a 2x higher rate of hysterectomies and 70% reported chronic dizziness and fatigue during summer months.
- Workplace heat adaptation gaps – Informal sectors lack basic “survival infrastructure” like cooling or hydration, turning workplaces into health hazards.
E.g. In Tamil Nadu’s textile belts, female workers reported avoiding water to skip bathroom breaks, leading to a spike in Urinary Tract Infections (UTIs) during heatwaves (MSSRF data).
- Conditional WHO approval of GLP-1 weight-loss drugs – The WHO has backed drugs like Semaglutide but with strict “last-resort” guardrails.
E.g. The WHO guideline restricts Wegovy (Semaglutide) use to adults with BMI ≥35 who have failed lifestyle interventions, rejecting it as a cosmetic “quick fix.”
- AMR plan progress with coordination deficit – India’s NAP-AMR 2.0 sets targets, but state-level enforcement remains the weak link.
E.g. While Kerala and Gujarat successfully banned OTC antibiotic sales, other states lack similar enforcement, creating regulatory loopholes for drug resistance.
- HIV prevention shift to long-acting injection – A paradigm shift from daily pills to twice-yearly shots for HIV prevention.
E.g. South Africa secured 400,000 doses of Lenacapavir (a twice-yearly injection) via the Global Fund to target high-risk adolescent girls starting in early 2026.
- Regulatory tightening and AI surveillance – India is moving from reactive checks to predictive monitoring after global pharma trust deficits.
E.g. Following the Maiden Pharma tragedy in Gambia, India’s CDSCO audited 76 pharmaceutical firms, cancelling 18 licenses for manufacturing violations in a single drive.
Implications:
- Gendered climate health inequity deepens – Heat is not just uncomfortable; it is becoming a driver of gender-based violence and economic loss.
E.g. The MSSRF study noted a 38% increase in domestic violence reports during peak summer months in surveyed households, linked to economic stress and water scarcity.
- Therapeutic access divides widen – Advanced drugs (GLP-1s, Lenacapavir) risk becoming elite-only products without price controls.
E.g. WHO data projects that even with production scaling, GLP-1 drugs will reach less than 10% of the global population needing them by 2030 due to high costs (~$1000/month in US).
- AMR containment remains structurally fragile – Without federal-style accountability, national plans fail at the district level.
E.g. The “One Health” approach is stalling because veterinary antibiotic use (regulated by States) remains largely unchecked compared to human health sectors.
- Urban heat–cardiac vulnerability escalates – Cities are becoming heat traps, triggering “silent” metabolic and cardiac collapses.
E.g. Ahmedabad’s Heat Action Plan found that all-cause mortality spiked by 43% during heatwaves, prompting the integration of heat alerts with hospital admission data.
- Regulatory legitimacy tests intensify – Export safety is now directly linked to India’s “Pharmacy of the World” reputation.
E.g. In October 2024, samples of Coldrif Syrup (Sresan Pharmaceuticals) were found to contain 46% Diethylene Glycol (a toxic solvent) after causing deaths in Madhya Pradesh.
What can be done?
- Legislate heat-protective labour conditions – Mandate specific cooling amenities rather than general “welfare” norms.
E.g. Kerala’s Labour Department mandates a “noon break” (12 PM–3 PM) for outdoor workers between February and April to prevent heatstroke.
- Convert AMR timelines into binding enforcement – Move from voluntary state alignment to statutory mandates.
E.g. Adopting Kerala’s “Operation Amrith”, which empowers drug inspectors to conduct surprise raids and track antibiotic sales via a digital app, across all states.
- Ensure equitable access to GLP-1 and Lenacapavir – Use international licensing mechanisms to lower costs.
E.g. The Medicines Patent Pool (MPP) signed voluntary licensing deals with Indian generic makers (like Cipla/Dr. Reddy’s) to produce low-cost versions of Lenacapavir for 120 countries.
- Embed AI-heat-AQI mapping into urban health plans – Use technology to predict health risks before they peak.
E.g. The Nagpur Metropolitan Surveillance Unit used AI media scanning to detect an outbreak of Acute Encephalitis Syndrome (AES) in Chhindwara days before official reports.
- Modernise surveillance with unified audit layers – Combine export checks with domestic safety monitoring.
E.g. The Integrated Health Information Platform (IHIP) now aggregates real-time data from 33 disease conditions, allowing districts to spot “fever clusters” instantly.
Conclusion:
The convergence of heat-linked gender stressors, metabolic drug caution, AMR execution demands, and long-acting prevention signals a decisive turn in health governance. India’s resilience now rests not on episodic drug breakthroughs but on climate-aware design (like Kerala’s noon breaks), equity-proofing and strict institutional enforcement.
